KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aquestive Therapeutics (AQST) Receivables: 2017-2024

Historic Receivables for Aquestive Therapeutics (AQST) over the last 8 years, with Dec 2024 value amounting to $9.8 million.

  • Aquestive Therapeutics' Receivables rose 20.92% to $14.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $50.7 million, marking a year-over-year increase of 24.53%. This contributed to the annual value of $9.8 million for FY2024, which is 13.78% down from last year.
  • Aquestive Therapeutics' Receivables amounted to $9.8 million in FY2024, which was down 13.78% from $11.4 million recorded in FY2023.
  • In the past 5 years, Aquestive Therapeutics' Receivables registered a high of $18.1 million during FY2021, and its lowest value of $6.8 million during FY2022.
  • For the 3-year period, Aquestive Therapeutics' Receivables averaged around $9.3 million, with its median value being $9.8 million (2024).
  • In the last 5 years, Aquestive Therapeutics' Receivables slumped by 62.24% in 2022 and then surged by 66.39% in 2023.
  • Yearly analysis of 5 years shows Aquestive Therapeutics' Receivables stood at $14.0 million in 2020, then climbed by 29.85% to $18.1 million in 2021, then tumbled by 62.24% to $6.8 million in 2022, then soared by 66.39% to $11.4 million in 2023, then dropped by 13.78% to $9.8 million in 2024.